PNPLA3 I148M and response to treatment for hepatic steatosis. A systematic review.
Joost BoeckmansAlexandra GatziosJörn Markus SchattenbergGer H KoekRobim M RodriguesTamara VanhaeckePublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
NAFLD patients homozygous for the PNPLA3 148M allele might not benefit from omega-3 carboxylic acids to reduce hepatic steatosis, in contrast to patients with wildtype PNPLA3. Instead, patients with two PNPLA3 148M alleles should be especially encouraged to adopt lifestyle changes. Genotyping for PNPLA3 I148M should be encouraged in therapeutic studies for NAFLD. PROSPERO registration number: CRD42022375028.